ULCERATIVE COLITIS (UC)

This study looks at whether adding CurQD, a supplement made from curcumin and QingDai, helps people with active ulcerative colitis who are already taking Vedolizumab. Researchers will review medical records from 400 patients to see if adding CurQD helps them stay on Vedolizumab l…

This study tests whether the drug risankizumab can help people with ulcerative colitis stay in remission (symptom-free) for a full year. It includes over 1,200 adults who already improved with risankizumab in an earlier study. Participants receive either the drug or a placebo for…

This study compares two treatments for Crohn's disease and ulcerative colitis: using the injectable drug infliximab alone versus combining it with another immune-suppressing pill. The goal is to see if the single drug is just as good at keeping patients in remission without stero…

This study looks at the long-term safety and effectiveness of a daily pill called upadacitinib for people with ulcerative colitis, a chronic bowel disease causing inflammation and ulcers. About 950 adults who didn't get better with earlier treatments or lost response will take th…

This study reviews medical records of 120 adults with inflammatory bowel disease (Crohn's or ulcerative colitis) who switched from intravenous to subcutaneous (under-the-skin) vedolizumab. Researchers want to see if patients stay in remission and what dosing patterns doctors use …

This early-phase study tests the safety and tolerability of a single dose of ALTB-268 given intravenously to 24 healthy adults. The goal is to see how the body handles the drug and identify any side effects before moving to patient studies. This is a first step toward developing …

This study aims to understand how inflammatory bowel disease (IBD) impacts quality of life. Researchers will survey 385 adults with Crohn's disease or ulcerative colitis about their symptoms, emotions, social support, and daily functioning. No treatments or medications are tested…

This study is collecting health information from 2000 people with Crohn's disease or ulcerative colitis to create tools that predict how well different treatments will work. The goal is to help doctors choose the right biologic or small-molecule drug for each patient. Participant…